4D Molecular Therapeutics Engages at Genetic Medicines Conference
4D Molecular Therapeutics Participates in Key Conference
EMERYVILLE, Calif. – 4D Molecular Therapeutics (NASDAQ: FDMT), a prominent late-stage biotechnology company, has announced its participation in Chardan's 9th Annual Genetic Medicines Conference. This event focuses on significant advancements in genetic therapies that have the potential to change the healthcare landscape.
Understanding the Conference Details
The conference is a platform for leaders in biotechnology to share insights and engage in discussions about the future of medical science. 4DMT's management will engage in panel discussions that highlight novel gene therapies.
Panel Discussions Overview
One of the notable discussions will center around "In Vivo Gene Therapy: Breaking into Competitive Ophthalmic Indications". This panel is slated for 9:30 a.m. ET. Another critical presentation is titled "In Vivo Gene Therapies in the Lung: Treating CF and Beyond", scheduled for 2:00 p.m. ET. Participation in these panels signifies 4DMT's commitment to addressing significant therapeutic challenges.
Archived Webcasts Available
For those unable to attend, archived webcasts of the presentations will be accessible for up to one year on the 4DMT website under the "Investors" section. This allows stakeholders and interested parties to stay informed about the latest developments and insights shared during the conference.
About 4D Molecular Therapeutics
4DMT is recognized for its commitment to developing durable, disease-targeted therapeutics. The company aims to transform treatment paradigms, especially concerning conditions that currently lack effective therapies. Their lead product candidate, 4D-150, is engineered to provide a multi-year sustained delivery of anti-VEGF treatments to patients with retinal diseases.
Key Developments in Their Pipeline
4D-150 is particularly aimed at treating age-related macular degeneration and diabetic macular edema, both of which are major contributors to vision loss. Another innovative candidate, 4D-710, is pioneering the delivery of genetic medicine for cystic fibrosis, demonstrating the company's innovative approach to potentially life-altering treatments.
Compliance and Future Prospects
While all of 4DMT's products are in clinical or preclinical stages, they're positioned to lead significant advancements in therapeutic areas. The company does not make any claims regarding the efficacy of its products until they are fully evaluated by regulatory authorities.
Contact Information for Inquiries
For further details regarding 4DMT's exciting developments or to reach out for investor relations, interested parties can contact:
Media:
Jenn Gordon
dna Communications
Media@4DMT.com
Investors:
Julian Pei
Head of Investor Relations and Strategic Finance
Investor.Relations@4DMT.com
Frequently Asked Questions
What is 4D Molecular Therapeutics focused on?
4DMT is dedicated to advancing durable and disease-targeted therapies that can significantly enhance patient outcomes.
When is the Genetic Medicines Conference taking place?
The conference will occur on October 21, focusing on recent advancements in genetic therapies.
What are some products in 4DMT's pipeline?
The company is developing 4D-150 for retinal diseases and 4D-710 for cystic fibrosis, showcasing their innovative approach.
How can I access the conference webcasts?
The webcasts will be available for one year on 4DMT's website, under the "Investors" section, for those who wish to review the discussions.
Who can I contact for more information about 4DMT?
Inquiries can be directed to their media or investor relations teams via the provided email addresses.
About The Author
Contact Dominic Sanders privately here. Or send an email with ATTN: Dominic Sanders as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.